DK1330293T3 - Præparat til kontrolleret frigivelse omfattende mælkesyrepolymer og fremgangsmåde til fremstilling deraf - Google Patents

Præparat til kontrolleret frigivelse omfattende mælkesyrepolymer og fremgangsmåde til fremstilling deraf

Info

Publication number
DK1330293T3
DK1330293T3 DK02738838T DK02738838T DK1330293T3 DK 1330293 T3 DK1330293 T3 DK 1330293T3 DK 02738838 T DK02738838 T DK 02738838T DK 02738838 T DK02738838 T DK 02738838T DK 1330293 T3 DK1330293 T3 DK 1330293T3
Authority
DK
Denmark
Prior art keywords
preparation
lactic acid
controlled release
acid polymer
release preparation
Prior art date
Application number
DK02738838T
Other languages
English (en)
Other versions
DK1330293T4 (da
Inventor
Kazumichi Yamamoto
Akiko Yamada
Yoshio Hata
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26617910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1330293(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of DK1330293T3 publication Critical patent/DK1330293T3/da
Publication of DK1330293T4 publication Critical patent/DK1330293T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Moulds For Moulding Plastics Or The Like (AREA)
  • Lubricants (AREA)
DK02738838.8T 2001-06-29 2002-06-28 Præparat til kontrolleret frigivelse omfattende mælkesyrepolymer og fremgangsmåde til fremstilling deraf DK1330293T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001199484 2001-06-29
JP2001340993 2001-11-06
PCT/JP2002/006527 WO2003002092A2 (en) 2001-06-29 2002-06-28 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same

Publications (2)

Publication Number Publication Date
DK1330293T3 true DK1330293T3 (da) 2006-09-11
DK1330293T4 DK1330293T4 (da) 2011-01-10

Family

ID=26617910

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08003261.8T DK1949936T3 (da) 2001-06-29 2002-06-28 Sammensætning til kontrolleret frigivelse og fremgangsmåde til fremstilling deraf
DK02738838.8T DK1330293T4 (da) 2001-06-29 2002-06-28 Præparat til kontrolleret frigivelse omfattende mælkesyrepolymer og fremgangsmåde til fremstilling deraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK08003261.8T DK1949936T3 (da) 2001-06-29 2002-06-28 Sammensætning til kontrolleret frigivelse og fremgangsmåde til fremstilling deraf

Country Status (34)

Country Link
US (4) US7429559B2 (da)
EP (3) EP1330293B2 (da)
JP (5) JP2003206240A (da)
KR (2) KR100916173B1 (da)
CN (3) CN100348265C (da)
AR (2) AR034641A1 (da)
AT (3) ATE326264T1 (da)
AU (2) AU2002311631B2 (da)
BR (1) BRPI0210561B8 (da)
CA (1) CA2455392C (da)
CO (1) CO5540367A2 (da)
CR (1) CR11283A (da)
CY (2) CY1105071T1 (da)
CZ (1) CZ306327B6 (da)
DE (2) DE60225481T2 (da)
DK (2) DK1949936T3 (da)
ES (2) ES2366677T3 (da)
HK (1) HK1056332A1 (da)
HU (1) HU230351B1 (da)
IL (3) IL159059A0 (da)
MX (1) MXPA03011456A (da)
MY (1) MY142066A (da)
NO (1) NO331883B1 (da)
NZ (2) NZ529969A (da)
PE (1) PE20030066A1 (da)
PL (1) PL204903B1 (da)
PT (2) PT1330293E (da)
RU (1) RU2301661C2 (da)
SG (1) SG180015A1 (da)
SI (1) SI1949936T1 (da)
SK (1) SK287577B6 (da)
TW (2) TW200526267A (da)
WO (1) WO2003002092A2 (da)
ZA (1) ZA200309152B (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ505651A (en) 1998-01-16 2003-08-29 Takeda Chemical Industries Ltd Sustained release composition comprising biologically active substance, hydroxynaphthoic acid and biodegradable polymer
TW200526267A (en) * 2001-06-29 2005-08-16 Takeda Chemical Industries Ltd Controlled release composition and method of producing the same
TWI225416B (en) * 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
DK1532985T3 (da) * 2002-06-25 2016-12-05 Takeda Pharmaceuticals Co Fremgangsmåde til fremstilling af en sammensætning med langvarig frigivelse
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
PT1615959E (pt) * 2003-04-10 2013-08-29 Evonik Corp Um método para a produção de micropartículas à base de emulsão
US8871269B2 (en) * 2003-07-15 2014-10-28 Evonik Corporation Method for the preparation of controlled release formulations
CA2533592C (en) * 2003-07-23 2015-11-10 Pr Pharmaceuticals, Inc. Controlled release compositions
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
US20070149457A1 (en) * 2005-12-13 2007-06-28 Byron Rubin Stable solid forms of enterostatin
ES2397712T3 (es) 2006-01-18 2013-03-08 Qps, Llc Composiciones farmacéuticas con estabilidad reforzada
US7858663B1 (en) * 2007-10-31 2010-12-28 Pisgah Laboratories, Inc. Physical and chemical properties of thyroid hormone organic acid addition salts
WO2008075762A1 (en) 2006-12-18 2008-06-26 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same
US20110319987A1 (en) * 2009-05-20 2011-12-29 Arsenal Medical Medical implant
KR101811797B1 (ko) * 2013-04-03 2017-12-22 동국제약 주식회사 도네페질을 포함하는 비경구투여용 약제학적 조성물
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
CN103751851A (zh) * 2014-01-17 2014-04-30 东华大学 一种无机/有机多药物控释复合纳米纤维支架的制备方法
KR101558083B1 (ko) * 2014-04-07 2015-10-07 에스케이케미칼주식회사 약물함유 고분자미립구 제조방법
CN106456704A (zh) 2014-04-16 2017-02-22 Veyx-药物有限公司 兽药组合物和其应用
US10787920B2 (en) 2016-10-12 2020-09-29 General Electric Company Turbine engine inducer assembly
KR102089737B1 (ko) * 2017-11-01 2020-03-16 한국화학연구원 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법
WO2024095158A1 (en) 2022-10-31 2024-05-10 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3297033A (en) 1963-10-31 1967-01-10 American Cyanamid Co Surgical sutures
US3565869A (en) 1968-12-23 1971-02-23 American Cyanamid Co Extrudable and stretchable polyglycolic acid and process for preparing same
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3755558A (en) 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US3839297A (en) 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
US3912692A (en) 1973-05-03 1975-10-14 American Cyanamid Co Process for polymerizing a substantially pure glycolide composition
US3890283A (en) 1973-06-04 1975-06-17 American Cyanamid Co Process for post-polymerizing polyglycolic acid
US4258063A (en) 1978-06-23 1981-03-24 Henkel Corporation Self-emulsifying cosmetic base
US4249531A (en) 1979-07-05 1981-02-10 Alza Corporation Bioerodible system for delivering drug manufactured from poly(carboxylic acid)
US4273920A (en) 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4479911A (en) 1982-01-28 1984-10-30 Sandoz, Inc. Process for preparation of microspheres and modification of release rate of core material
US4605730A (en) 1982-10-01 1986-08-12 Ethicon, Inc. Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same
US4539981A (en) 1982-11-08 1985-09-10 Johnson & Johnson Products, Inc. Absorbable bone fixation device
FR2537980B1 (fr) 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JPH0678425B2 (ja) 1984-07-06 1994-10-05 和光純薬工業株式会社 重合体の新規製造法
CA1256638A (en) 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
DE3678308D1 (de) 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
EP0452111B1 (en) * 1990-04-13 1998-07-15 Takeda Chemical Industries, Ltd. Biodegradable high-molecular polymers, production and use thereof
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
US5353086A (en) * 1993-05-03 1994-10-04 Eastman Kodak Company Textured surface with canted channels for an automatic tray processor
DE4342092B4 (de) * 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
JP3490171B2 (ja) 1994-02-21 2004-01-26 武田薬品工業株式会社 生体内分解性ポリマーの末端カルボキシル基におけるエステル
US5594091A (en) 1994-02-21 1997-01-14 Takeda Chemical Industries, Ltd. Matrix for sustained-release preparation
US5763513A (en) 1994-05-19 1998-06-09 Mitsui Toatsu Chemicals, Inc. L-lactic acid polymer composition, molded product and film
JPH08259460A (ja) * 1995-01-23 1996-10-08 Takeda Chem Ind Ltd 徐放性製剤の製造法
JP3902272B2 (ja) * 1995-09-04 2007-04-04 武田薬品工業株式会社 徐放性製剤の製造法
US5922662A (en) * 1996-08-07 1999-07-13 Colgate Palmolive Company High foaming nonionic surfactant based liquid detergent
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
JPH10273447A (ja) * 1997-01-29 1998-10-13 Takeda Chem Ind Ltd 徐放性マイクロスフィア、その製造法および用途
AU5678398A (en) 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
NZ505651A (en) 1998-01-16 2003-08-29 Takeda Chemical Industries Ltd Sustained release composition comprising biologically active substance, hydroxynaphthoic acid and biodegradable polymer
JPH11269094A (ja) 1998-01-16 1999-10-05 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途
US6114495A (en) 1998-04-01 2000-09-05 Cargill Incorporated Lactic acid residue containing polymer composition and product having improved stability, and method for preparation and use thereof
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
DE69923795T2 (de) * 1998-12-15 2006-03-16 Takeda Pharmaceutical Co. Ltd. Verfahren zur Herstellung biologisch-abbaubarer Polyester
JP2000238051A (ja) † 1999-02-23 2000-09-05 Kansei Corp 表皮シートの発泡成形型へのセッティング方法
NZ516466A (en) * 1999-07-15 2003-02-28 Takeda Chemical Industries Ltd Sustained release compositions, process for producing the same and use thereof
JP2001081043A (ja) * 1999-07-15 2001-03-27 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途
JP3837607B2 (ja) † 2000-05-29 2006-10-25 Ｔｃｍ株式会社 マスト用溶接位置決め治具
ATE322513T1 (de) 2000-08-07 2006-04-15 Wako Pure Chem Ind Ltd Milchsäurepolymer und verfahren zu dessen herstellung
AU2002218494A1 (en) 2000-11-29 2002-06-11 Takeda Chemical Industries Ltd. Medicinal compositions and process for producing the same
WO2002047722A1 (fr) * 2000-12-15 2002-06-20 Takeda Chemical Industries, Ltd. Compositions medicinales agoniste ou antagoniste de la gonadoliberine non peptidyl, methode de production et utilisation desdites compositions
TW200526267A (en) * 2001-06-29 2005-08-16 Takeda Chemical Industries Ltd Controlled release composition and method of producing the same

Also Published As

Publication number Publication date
US7429559B2 (en) 2008-09-30
HUP0400378A2 (hu) 2004-12-28
IL159059A0 (en) 2004-05-12
US8246987B2 (en) 2012-08-21
CO5540367A2 (es) 2005-07-29
JP2010189428A (ja) 2010-09-02
EP1949936A3 (en) 2008-10-08
EP1491236B1 (en) 2008-03-05
DE60211464D1 (de) 2006-06-22
HUP0400378A3 (en) 2010-01-28
HU230351B1 (hu) 2016-02-29
NO20035738L (no) 2004-02-27
ES2263788T3 (es) 2006-12-16
WO2003002092A2 (en) 2003-01-09
IL186782A0 (en) 2008-02-09
DK1330293T4 (da) 2011-01-10
EP1491236A1 (en) 2004-12-29
PL204903B1 (pl) 2010-02-26
EP1949936B1 (en) 2011-05-18
PT1949936E (pt) 2011-07-12
EP1330293B2 (en) 2010-10-27
KR100916173B1 (ko) 2009-09-08
JP2009167203A (ja) 2009-07-30
DK1949936T3 (da) 2011-08-15
EP1330293B1 (en) 2006-05-17
KR20040018402A (ko) 2004-03-03
CY1111708T1 (el) 2015-10-07
US20110166084A1 (en) 2011-07-07
AU2002311631B2 (en) 2007-02-08
SI1949936T1 (sl) 2011-08-31
KR20090020708A (ko) 2009-02-26
ES2366677T3 (es) 2011-10-24
AR098261A2 (es) 2016-05-18
PE20030066A1 (es) 2003-03-20
CN1535168A (zh) 2004-10-06
AU2006246508A1 (en) 2006-12-21
NO331883B1 (no) 2012-04-23
NZ541884A (en) 2007-01-26
HK1056332A1 (en) 2004-02-13
CZ20033493A3 (cs) 2004-08-18
JP2003206240A (ja) 2003-07-22
AR034641A1 (es) 2004-03-03
ATE387937T1 (de) 2008-03-15
US8815801B2 (en) 2014-08-26
CR11283A (es) 2010-05-31
SG180015A1 (en) 2012-05-30
CY1105071T1 (el) 2010-03-03
IL159059A (en) 2011-06-30
BRPI0210561B8 (pt) 2021-05-25
ES2263788T5 (es) 2011-02-22
BRPI0210561B1 (pt) 2018-08-14
ATE509668T1 (de) 2011-06-15
JP4819173B2 (ja) 2011-11-24
SK15602003A3 (sk) 2004-06-08
AU2006246508B2 (en) 2008-09-04
EP1330293A2 (en) 2003-07-30
CA2455392A1 (en) 2003-01-09
JP2010189427A (ja) 2010-09-02
BR0210561A (pt) 2004-06-22
CN1868458A (zh) 2006-11-29
CN100348265C (zh) 2007-11-14
CZ306327B6 (cs) 2016-12-07
MY142066A (en) 2010-08-30
CA2455392C (en) 2011-11-22
US8067030B2 (en) 2011-11-29
ZA200309152B (en) 2005-01-26
RU2301661C2 (ru) 2007-06-27
MXPA03011456A (es) 2004-07-01
EP1949936A2 (en) 2008-07-30
TW200526267A (en) 2005-08-16
NZ529969A (en) 2005-10-28
JP4819172B2 (ja) 2011-11-24
DE60211464T2 (de) 2006-09-07
PL367518A1 (en) 2005-02-21
US20030134800A1 (en) 2003-07-17
CN1724066A (zh) 2006-01-25
DE60225481D1 (de) 2008-04-17
DE60211464T3 (de) 2011-03-17
PT1330293E (pt) 2006-08-31
US20090005318A1 (en) 2009-01-01
CN1292796C (zh) 2007-01-03
DE60225481T2 (de) 2009-02-26
US20120283187A1 (en) 2012-11-08
SK287577B6 (sk) 2011-03-04
ATE326264T1 (de) 2006-06-15
TWI332407B (en) 2010-11-01
JP2004238400A (ja) 2004-08-26
RU2004102507A (ru) 2005-03-10
WO2003002092A3 (en) 2003-04-10
CN100577206C (zh) 2010-01-06
NO20035738D0 (no) 2003-12-19
KR100961413B1 (ko) 2010-06-09

Similar Documents

Publication Publication Date Title
DK1330293T3 (da) Præparat til kontrolleret frigivelse omfattende mælkesyrepolymer og fremgangsmåde til fremstilling deraf
DK1399133T3 (da) Langvarig frigörelsessammensætning omfattende mælkesyre-glycolsyre copolymer og fremgangsmåde til fremstilling af disse
DK1180518T3 (da) 5-pyridyl-1,3-azolforbindelser, fremgangsmåde til fremstilling deraf og anvendelse deraf
EP1832298A4 (en) MATRIX-TYPE-CONTROLLED RELEASE PREPARATION COMPRISING A BASIC SUBSTANCE OR SALT THEREOF AND PROCESS FOR PRODUCTION THEREOF
ATE464050T1 (de) Aripiprazole wirkstoff mit niedriger hygroskopie und verfahren zu ihrer herstellung
AR028387A1 (es) Forcps quirurgico miniaturizado y metodos para su produccion
IS7188A (is) Asabísýklísk-setin samtengd heteróarýl efnasambönd, aðferð til framleiðslu þeirra og notkun
DK1449917T3 (da) Fremgangsmåde til L-aminosyrefremstilling under anvendelse af Escherichia
DE60238439D1 (de) Wasserabsorbierende polymere und verfahren zu deren herstellung
IS6724A (is) Aðferð til framleiðslu á N-arýl-anþranilískum sýrum og afleiðum þeirra
NO20012158D0 (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
GB0319817D0 (en) Microcapsules method for preparing same and use thereof
NO20021736D0 (no) Nytt preparat og fremgangsmåte for stabilisering av det
AU2003272341A1 (en) Methods and compositions for blood pool identification, drug distribution quantification and drug release verification
AU2002331254A1 (en) Device and method for preparing blood
NO20023868D0 (no) Forgrenete polymere overflateaktiv-middel reaksjonsprodukter, samt fremgangsmåter for fremstilling og anvendelse derav
DK1276760T3 (da) Polyamidnukleinsyrederivater, middel og fremgangsmåde til deres fremstilling
EP1660437A4 (en) Hydroxamic acid derivatives and process for their preparation
ZA200308687B (en) Method and device for the two-step production of acrylic acid.
NO20013735L (no) Fremgangsmåte til fremstilling av di-iso-butaner, di-iso- butener og di-n-butener fra feltbutaner
DE60109407D1 (de) Taumelscheibe und Verfahren zu ihrer Herstellung
NO20031844L (no) Nye askorbinsyreforbindelser, fremgangsmåter for fremstilling derav og anvendelse derav
NO20033120D0 (no) 2-arylimino-2,3-dihydrotiazolderivater, fremgangsmater for fremstilling derav og terapeutisk anvendelse derav
DK1282639T3 (da) Polyamidnucleinsyrederivater, midler og fremgangsmåder til fremstilling heraf
ZA200307382B (en) Controlled release urea product and method of preparing said product.